LungLife AI, Inc. Share Price Deutsche Boerse AG
Equities
9H4
USU5500L1045
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.184 EUR | 0.00% | -5.15% | -74.79% |
04-05 | Transcript : LungLife AI, Inc., 2023 Earnings Call, Apr 05, 2024 | |
04-04 | LungLife reports narrowed losses in year of "considerable achievement" | AN |
Sales 2024 * | 100K 93.44K 7.89M | Sales 2025 * | 500K 467K 39.43M | Capitalization | 6.61M 6.18M 521M |
---|---|---|---|---|---|
Net income 2024 * | -3M -2.8M -237M | Net income 2025 * | - 0 0 | EV / Sales 2024 * | 60.1 x |
Net cash position 2024 * | 600K 561K 47.31M | Net cash position 2025 * | 500K 467K 39.43M | EV / Sales 2025 * | 12.2 x |
P/E ratio 2024 * |
-1.6
x | P/E ratio 2025 * |
53.6
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.29% |
Latest transcript on LungLife AI, Inc.
1 week | -5.15% | ||
Current month | -9.80% | ||
1 month | -34.75% | ||
3 months | -42.14% | ||
6 months | -76.71% | ||
Current year | -74.79% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Pagano
CEO | Chief Executive Officer | 40 | - |
David Anderson
DFI | Director of Finance/CFO | 61 | - |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gordon Davis
CHM | Chairman | 67 | 07/07/21 |
Andrew Boteler
BRD | Director/Board Member | 58 | 07/07/21 |
David Anderson
DFI | Director of Finance/CFO | 61 | - |
Date | Price | Change |
---|---|---|
14/06/24 | 0.184 | 0.00% |
13/06/24 | 0.184 | 0.00% |
12/06/24 | 0.184 | -6.12% |
11/06/24 | 0.196 | +0.51% |
10/06/24 | 0.195 | +0.52% |
Delayed Quote Deutsche Boerse AG, June 14, 2024 at 02:29 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.68% | 3.7B | |
+0.37% | 2.28B | |
-21.21% | 1.99B | |
-23.77% | 1.6B | |
+14.81% | 999M | |
+18.25% | 739M | |
-10.04% | 685M | |
-36.12% | 461M | |
-4.47% | 279M |
- Stock Market
- Equities
- LLAI Stock
- 9H4 Stock